Orlando Santana1, Steve Xydas2, Roy F Williams2, Maurice Mawad2, Todd B Heimowitz1, Andrés M Pineda3, Howard S Goldman4, Christos G Mihos5. 1. Division of Cardiology, The Columbia University, Mount Sinai Heart Institute, Miami Beach, FL, USA. 2. Division of Cardiac Surgery, Mount Sinai Heart Institute, Miami Beach, FL, USA. 3. Cardiac Catheterization Laboratory, Duke University Medical Center, Durham, UK. 4. Department of Anesthesia, Mount Sinai Medical Center, Miami Beach, FL, USA. 5. Cardiac Ultrasound Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: The current study evaluated the safety and feasibility of staged ("hybrid") percutaneous coronary intervention (PCI) followed by isolated minimally invasive mitral valve (MV) surgery [PCI + minimally invasive mitral valve surgery (MIMVS)], for patients with concomitant coronary artery and MV disease. METHODS: A total of 93 patients who underwent PCI + MIMVS for coronary artery and MV disease between February 2009 and April 2014 were retrospectively analyzed. RESULTS: There were 54 (58.1%) men and 39 (41.9%) women. The mean age was 73±8 years, and all patients had severe mitral regurgitation. PCI was performed for single-vessel coronary artery disease in 40 (43%) patients, two-vessel in 49 (52.7%), and three-vessel in 4 (4.3%). Within a median of 48 days (IQR, 18-71) after PCI, 78 (83.9%) patients underwent primary valve surgery, and 15 (16.1%) underwent re-operative valve surgery, with 56 (60.2%) having MV replacement, and 37 (39.8%) having MV repair. Sixty-five (69.9%) patients were being treated with dual anti-platelet therapy at the time of surgery. The median number of transfused intra-operative red blood cell units was 1 (IQR, 0-2), and the intensive care unit and hospital lengths of stay were 46 hours (IQR, 27-76) and 8 days (IQR, 5-11), respectively. Post-operatively, there was 1 (1.1%) cerebrovascular accident, 2 (2.2%) patients developed acute kidney injury, and 4 (4.3%) required a re-operation for bleeding. Thirty-day mortality occurred in 4 (4.3%) patients. At a mean follow-up of 15.3±13.2 months, 3 (3.4%) patients required target-vessel revascularization. The survival rate was 89% and 85% at 1 and 3 years, respectively. CONCLUSIONS: In patients with concomitant coronary artery and MV disease, PCI + MIMVS can be safely performed and is associated with good short-term and follow-up outcomes.
BACKGROUND: The current study evaluated the safety and feasibility of staged ("hybrid") percutaneous coronary intervention (PCI) followed by isolated minimally invasive mitral valve (MV) surgery [PCI + minimally invasive mitral valve surgery (MIMVS)], for patients with concomitant coronary artery and MV disease. METHODS: A total of 93 patients who underwent PCI + MIMVS for coronary artery and MV disease between February 2009 and April 2014 were retrospectively analyzed. RESULTS: There were 54 (58.1%) men and 39 (41.9%) women. The mean age was 73±8 years, and all patients had severe mitral regurgitation. PCI was performed for single-vessel coronary artery disease in 40 (43%) patients, two-vessel in 49 (52.7%), and three-vessel in 4 (4.3%). Within a median of 48 days (IQR, 18-71) after PCI, 78 (83.9%) patients underwent primary valve surgery, and 15 (16.1%) underwent re-operative valve surgery, with 56 (60.2%) having MV replacement, and 37 (39.8%) having MV repair. Sixty-five (69.9%) patients were being treated with dual anti-platelet therapy at the time of surgery. The median number of transfused intra-operative red blood cell units was 1 (IQR, 0-2), and the intensive care unit and hospital lengths of stay were 46 hours (IQR, 27-76) and 8 days (IQR, 5-11), respectively. Post-operatively, there was 1 (1.1%) cerebrovascular accident, 2 (2.2%) patients developed acute kidney injury, and 4 (4.3%) required a re-operation for bleeding. Thirty-day mortality occurred in 4 (4.3%) patients. At a mean follow-up of 15.3±13.2 months, 3 (3.4%) patients required target-vessel revascularization. The survival rate was 89% and 85% at 1 and 3 years, respectively. CONCLUSIONS: In patients with concomitant coronary artery and MV disease, PCI + MIMVS can be safely performed and is associated with good short-term and follow-up outcomes.
Authors: John G Byrne; Marzia Leacche; Daniel Unic; James D Rawn; Daniel I Simon; Campbell D Rogers; Lawrence H Cohn Journal: J Am Coll Cardiol Date: 2005-01-04 Impact factor: 24.094
Authors: David M Shahian; Sean M O'Brien; Giovanni Filardo; Victor A Ferraris; Constance K Haan; Jeffrey B Rich; Sharon-Lise T Normand; Elizabeth R DeLong; Cynthia M Shewan; Rachel S Dokholyan; Eric D Peterson; Fred H Edwards; Richard P Anderson Journal: Ann Thorac Surg Date: 2009-07 Impact factor: 4.330
Authors: Orlando Santana; Sandeep Singla; Christos G Mihos; Andrés M Pineda; Gregg W Stone; Paul A Kurlansky; Isaac George; Ajay J Kirtane; Craig R Smith; Nirat Beohar Journal: Innovations (Phila) Date: 2017 Jan/Feb
Authors: Davy C H Cheng; Janet Martin; Avtar Lal; Anno Diegeler; Thierry A Folliguet; L Wiley Nifong; Patrick Perier; Ehud Raanani; J Michael Smith; Joerg Seeburger; Volkmar Falk Journal: Innovations (Phila) Date: 2011-03